Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant | Zendy

Robert J. Lechleider | Zendy; Philip M. Arlen | Zendy; Kwong-Yok Tsang | Zendy; Seth M. Steinberg | Zendy; Junko Yokokawa | Zendy; Vittore Cereda | Zendy; Kevin Camphausen | Zendy; Jeffrey Schlom | Zendy; William L. Dahut | Zendy; James L. Gulley | Zendy

Open Access

Safety and Immunologic Response of a Viral Vaccine to Prostate-Specific Antigen in Combination with Radiation Therapy when Metronomic-Dose Interleukin 2 Is Used as an Adjuvant

Author(s) -

Robert J. Lechleider,

Philip M. Arlen,

Kwong-Yok Tsang,

Seth M. Steinberg,

Junko Yokokawa,

Vittore Cereda,

Kevin Camphausen,

Jeffrey Schlom,

William L. Dahut,

James L. Gulley

Publication year - 2008

Publication title -

clinical cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.427

H-Index - 324

eISSN - 1557-3265

pISSN - 1078-0432

DOI - 10.1158/1078-0432.ccr-07-5162

Subject(s) - medicine , adjuvant , immunology , antigen , vaccine therapy , immunotherapy , prostate specific antigen , radiation therapy , immune system , prostate cancer , cancer

We have previously reported on the safety and immunologic response of a poxvirus-based vaccine encoding prostate-specific antigen (PSA) used in combination with radiation therapy in patients with localized prostate cancer. We hypothesized that a "metronomic" dose of interleukin 2 (IL-2) as a biological adjuvant would cause less toxicity while maintaining immunologic response.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research